Initial symptom severity of bipolar I disorder and the efficacy of olanzapine: a meta-analysis of individual participant data from five placebo-controlled studies

The Lancet Psychiatry

Volumn 4, Issue 11, 2017, Pages 859-867

  Samara, Myrto T ^a,b   Goldberg, Yair ^c   Levine, Stephen Z ^c   Furukawa, Toshi A ^d   Geddes, John R ^e,f   Cipriani, Andrea ^e,f   Davis, John M ^g,h   Leucht, Stefan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c UNIVERSITY OF HAIFA   (Israel)

^d KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f WARNEFORD HOSPITAL   (United Kingdom)

^g UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^h UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; NEUROLEPTIC AGENT;

ARTICLE; BIPOLAR I DISORDER; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; MANIA; MENTAL PATIENT; META ANALYSIS; PLACEBO EFFECT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYMPTOM; TREATMENT DURATION; YOUNG MANIA RATING SCALE; BIPOLAR DISORDER; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; HUMANS; OLANZAPINE; OUTCOME ASSESSMENT (HEALTH CARE); SEVERITY OF ILLNESS INDEX;

EID: 85029597176     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(17)30331-0     Document Type: Article

References (48)

1. Goodwin, GM, Haddad, PM, Ferrier, IN, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 30 (2016), 495–553.
2. Kirsch, I, Deacon, BJ, Huedo-Medina, TB, Scoboria, A, Moore, TJ, Johnson, BT, Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med, 5, 2008, e45.
3. Fournier, JC, DeRubeis, RJ, Hollon, SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 303 (2010), 47–53.
4. Gibbons, RD, Hur, K, Brown, CH, Davis, JM, Mann, JJ, Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 69 (2012), 572–579.
5. Rabinowitz, J, Werbeloff, N, Mandel, FS, Menard, F, Marangell, L, Kapur, S, Initial depression severity and response to antidepressants v. placebo: patient-level data analysis from 34 randomised controlled trials. Br J Psychiatry 209 (2016), 427–428.
6. Hyman, M, Why antidepressants don't work for treating depression. http://www.huffingtonpost.com/dr-mark-hyman/depression-medication-why_b_550098.html, 2010 (accessed Jan 15, 2017).
7. Furukawa, TA, Levine, SZ, Tanaka, S, et al. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. JAMA Psychiatry 72 (2015), 14–21.
8. Levine, SZ, Kodesh, A, Goldberg, Y, et al. Initial severity and efficacy of risperidone in autism: results from the RUPP trial. Eur Psychiatry 32 (2016), 16–20.
9. McIntyre, RS, Konarski, JZ, Jones, M, Paulsson, B, Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms. J Affect Disord 100:suppl 1 (2007), S5–14.
10. Suppes, T, Eudicone, J, McQuade, R, Pikalov, A 3rd, Carlson, B, Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. J Affect Disord 107 (2008), 145–154.
11. Yildiz, A, Vieta, E, Tohen, M, Baldessarini, RJ, Factors modifying drug and placebo responses in randomized trials for bipolar mania. Int J Neuropsychopharmacol 14 (2011), 863–875.
12. Glue, P, Herbison, P, Comparative efficacy and acceptability of combined antipsychotics and mood stabilizers versus individual drug classes for acute mania: network meta-analysis. Aust NZ J Psychiatry 49 (2015), 1215–1220.
13. Stewart, LA, Tierney, JF, To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. Eval Health Prof 25 (2002), 76–97.
14. Tohen, M, Jacobs, TG, Grundy, SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch Gen Psychiatry 57 (2000), 841–849.
15. Tohen, M, Kryzhanovskaya, L, Carlson, G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 164 (2007), 1547–1556.
16. Tohen, M, Sanger, TM, McElroy, SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 156 (1999), 702–709.
17. Tohen, M, Vieta, E, Goodwin, GM, et al. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. J Clin Psychiatry 69 (2008), 1776–1789.
18. Katagiri, H, Takita, Y, Tohen, M, Higuchi, T, Kanba, S, Takahashi, M, Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: a randomized, double-blind, placebo- and haloperidol-controlled study. J Affect Disord 136 (2012), 476–484.
19. Young, RC, Biggs, JT, Ziegler, VE, Meyer, DA, A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133 (1978), 429–435.
20. Cohen, J, Statistical power analysis in the behavioral sciences, 2nd edn., 1988, Lawrence Erlbaum Associates, Hillsdale.
21. Lukasiewicz, M, Gerard, S, Besnard, A, et al. Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort. Int J Methods Psychiatr Res 22 (2013), 46–58.
22. Sysko, R, Walsh, BT, A systematic review of placebo response in studies of bipolar mania. J Clin Psychiatry 68 (2007), 1213–1217.
23. Hedeker, D, Gibbons, RD, Longitudinal data analysis, 2006, John Wiley & Sons, Hoboken.
24. Schwarz, G, Gideon, E, Estimating the dimension of a model. Ann Stat 6 (1978), 461–464.
25. Pinheiro, J, Bates, D, DebRoy, S, Sarkar, D, nlme: Linear and nonliniear mixed effects models. R package version 3.1-117, 2014, R Foundation for Statistical Computing, Vienna.
26. Canty A, Ripley B. boot: Bootstrap R (S-Plus) functions. R package version 1.3-7. 2012.
27. Robinson, WS, Ecological correlations and the behavior of individuals. Am Sociol Rev 15 (1950), 351–357.
28. Welge, JA, Keck, PE Jr, Meinhold, JM, Predictors of response to treatment of acute bipolar manic episodes with divalproex sodium or placebo in 2 randomized, controlled, parallel-group trials. J Clin Psychopharmacol 24 (2004), 607–612.
29. Yildiz, A, Nikodem, M, Vieta, E, Correll, CU, Baldessarini, RJ, A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. Psychol Med 45 (2015), 299–317.
30. Yildiz, A, Vieta, E, Leucht, S, Baldessarini, RJ, Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology 36 (2011), 375–389.
31. Tarr, GP, Herbison, P, de la Barra, SL, Glue, P, Study design and patient characteristics and outcome in acute mania clinical trials. Bipolar Disord 13 (2011), 125–132.
32. Wilder, J, The law of initial value in neurology and psychiatry; facts and problems. J Nerv Ment Dis 125 (1957), 73–86.
33. Barnett, AG, van der Pols, JC, Dobson, AJ, Regression to the mean: what it is and how to deal with it. Int J Epidemiol 34 (2005), 215–220.
34. Chiolero, A, Paradis, G, Rich, B, Hanley, JA, Assessing the relationship between the baseline value of a continuous variable and subsequent change over time. Front Public Health, 1, 2013, 29.
35. Licht, RW, Limits of the applicability and generalizability of drug trials in mania. Bipolar Disord 4:suppl 1 (2002), 66–68.
36. Hoertel, N, Le Strat, Y, Lavaud, P, Dubertret, C, Limosin, F, Generalizability of clinical trial results for bipolar disorder to community samples: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 74 (2013), 265–270.
37. Malhi, GS, Lampe, L, Coulston, CM, et al. Mixed state discrimination: a DSM problem that won't go away?. J Affect Disord 158 (2014), 8–10.
38. Fountoulakis, KN, Yatham, L, Grunze, H, et al. The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 2: review, grading of the evidence, and a precise algorithm. Int J Neuropsychopharmacol 20 (2016), 121–179.
39. Yatham, LN, Kennedy, SH, Parikh, SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 15 (2013), 1–44.
40. Tohen, M, Greil, W, Calabrese, JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 162 (2005), 1281–1290.
41. Grande, I, Bernardo, M, Bobes, J, Saiz-Ruiz, J, Alamo, C, Vieta, E, Antipsychotic switching in bipolar disorders: a systematic review. Int J Neuropsychopharmacol 17 (2014), 497–507.
42. Khan, A, Brodhead, AE, Kolts, RL, Brown, WA, Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. J Psychiatr Res 39 (2005), 145–150.
43. Melander, H, Salmonson, T, Abadie, E, van Zwieten-Boot, B, A regulatory Apologia—a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol 18 (2008), 623–627.
44. Khan, A, Leventhal, RM, Khan, SR, Brown, WA, Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol 22 (2002), 40–45.
45. Locher, C, Kossowsky, J, Gaab, J, Kirsch, I, Bain, P, Krummenacher, P, Moderation of antidepressant and placebo outcomes by baseline severity in late-life depression: a systematic review and meta-analysis. J Affect Disord 181 (2015), 50–60.
46. Nelson, JC, Delucchi, KL, Schneider, LS, Moderators of outcome in late-life depression: a patient-level meta-analysis. Am J Psychiatry 170 (2013), 651–659.
47. Huhn, M, Tardy, M, Spineli, LM, et al. Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses. JAMA Psychiatry 71 (2014), 706–715.
48. Fung, LK, Mahajan, R, Nozzolillo, A, et al. Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis. Pediatrics 137:suppl 2 (2016), S124–S135.